|
1
|
Braga EA, Burdennyy AM, Uroshlev LA, Zaichenko DM, Filippova EA, Lukina SS, Pronina IV, Astafeva IR, Fridman MV, Kazubskaya TP, Loginov VI, Dmitriev AA, Moskovtsev AA, Kushlinskii NE. Ten Hypermethylated lncRNA Genes Are Specifically Involved in the Initiation, Progression, and Lymphatic and Peritoneal Metastasis of Epithelial Ovarian Cancer. Int J Mol Sci 2024; 25:11843. [PMID: 39519394 PMCID: PMC11547154 DOI: 10.3390/ijms252111843] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2024] [Revised: 10/27/2024] [Accepted: 10/29/2024] [Indexed: 11/16/2024] Open
Abstract
Our work aimed to evaluate and differentiate the role of ten lncRNA genes (GAS5, HAND2-AS1, KCNK15-AS1, MAGI2-AS3, MEG3, SEMA3B-AS1, SNHG6, SSTR5-AS1, ZEB1-AS1, and ZNF667-AS1) in the development and progression of epithelial ovarian cancer (EOC). A representative set of clinical samples was used: 140 primary tumors from patients without and with metastases and 59 peritoneal metastases. Using MS-qPCR, we demonstrated an increase in methylation levels of all ten lncRNA genes in tumors compared to normal tissues (p < 0.001). Using RT-qPCR, we showed downregulation and an inverse relationship between methylation and expression levels for ten lncRNAs (rs < -0.5). We further identified lncRNA genes that were specifically hypermethylated in tumors from patients with metastases to lymph nodes (HAND2-AS1), peritoneum (KCNK15-AS1, MEG3, and SEMA3B-AS1), and greater omentum (MEG3, SEMA3B-AS1, and ZNF667-AS1). The same four lncRNA genes involved in peritoneal spread were associated with clinical stage and tumor extent (p < 0.001). Interestingly, we found a reversion from increase to decrease in the hypermethylation level of five metastasis-related lncRNA genes (MEG3, SEMA3B-AS1, SSTR5-AS1, ZEB1-AS1, and ZNF667-AS1) in 59 peritoneal metastases. This reversion may be associated with partial epithelial-mesenchymal transition (EMT) in metastatic cells, as indicated by a decrease in the level of the EMT marker, CDH1 mRNA (p < 0.01). Furthermore, novel mRNA targets and regulated miRNAs were predicted for a number of the studied lncRNAs using the NCBI GEO datasets and analyzed by RT-qPCR and transfection of SKOV3 and OVCAR3 cells. In addition, hypermethylation of SEMA3B-AS1, SSTR5-AS1, and ZNF667-AS1 genes was proposed as a marker for overall survival in patients with EOC.
Collapse
Affiliation(s)
- Eleonora A. Braga
- Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia; (A.M.B.); (D.M.Z.); (E.A.F.); (S.S.L.); (I.V.P.); (I.R.A.); (V.I.L.); (A.A.M.)
| | - Alexey M. Burdennyy
- Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia; (A.M.B.); (D.M.Z.); (E.A.F.); (S.S.L.); (I.V.P.); (I.R.A.); (V.I.L.); (A.A.M.)
| | - Leonid A. Uroshlev
- Vavilov Institute of General Genetics, Russian Academy of Sciences, 119991 Moscow, Russia; (L.A.U.); (M.V.F.)
| | - Danila M. Zaichenko
- Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia; (A.M.B.); (D.M.Z.); (E.A.F.); (S.S.L.); (I.V.P.); (I.R.A.); (V.I.L.); (A.A.M.)
| | - Elena A. Filippova
- Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia; (A.M.B.); (D.M.Z.); (E.A.F.); (S.S.L.); (I.V.P.); (I.R.A.); (V.I.L.); (A.A.M.)
| | - Svetlana S. Lukina
- Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia; (A.M.B.); (D.M.Z.); (E.A.F.); (S.S.L.); (I.V.P.); (I.R.A.); (V.I.L.); (A.A.M.)
| | - Irina V. Pronina
- Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia; (A.M.B.); (D.M.Z.); (E.A.F.); (S.S.L.); (I.V.P.); (I.R.A.); (V.I.L.); (A.A.M.)
| | - Iana R. Astafeva
- Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia; (A.M.B.); (D.M.Z.); (E.A.F.); (S.S.L.); (I.V.P.); (I.R.A.); (V.I.L.); (A.A.M.)
| | - Marina V. Fridman
- Vavilov Institute of General Genetics, Russian Academy of Sciences, 119991 Moscow, Russia; (L.A.U.); (M.V.F.)
| | - Tatiana P. Kazubskaya
- N.N. Blokhin National Medical Research Center of Oncology, 115478 Moscow, Russia; (T.P.K.); (N.E.K.)
| | - Vitaly I. Loginov
- Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia; (A.M.B.); (D.M.Z.); (E.A.F.); (S.S.L.); (I.V.P.); (I.R.A.); (V.I.L.); (A.A.M.)
| | - Alexey A. Dmitriev
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia;
| | - Aleksey A. Moskovtsev
- Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia; (A.M.B.); (D.M.Z.); (E.A.F.); (S.S.L.); (I.V.P.); (I.R.A.); (V.I.L.); (A.A.M.)
- N.N. Blokhin National Medical Research Center of Oncology, 115478 Moscow, Russia; (T.P.K.); (N.E.K.)
- Russian Medical Academy of Continuing Professional Education, 125993 Moscow, Russia
| | - Nikolay E. Kushlinskii
- N.N. Blokhin National Medical Research Center of Oncology, 115478 Moscow, Russia; (T.P.K.); (N.E.K.)
| |
Collapse
|
|
2
|
Tang Z, Jiang Y, Zong Y, Ding S, Wu C, Tang Z, Liao L, Jiang S, Tang R, Li F, Luo P. LncRNA SSTR5-AS1 promotes esophageal carcinoma through regulating ITGB6/JAK1/STAT3 signaling. Epigenomics 2024; 16:1133-1148. [PMID: 39234955 PMCID: PMC11457597 DOI: 10.1080/17501911.2024.2388018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2024] [Accepted: 07/31/2024] [Indexed: 09/06/2024] Open
Abstract
Aim: To investigate function of somatostatin receptor 5 antisense RNA 1 (SSTR5-AS1) in esophageal carcinoma (ESCA).Materials & methods: The cellular function was assessed using EdU staining and Transwell assay. The localization of SSTR5-AS1 was measured using fluorescence in situ hybridization staining.Results: SSTR5-AS1 shRNA repressed invasion and migration and induced apoptosis in ESCA cells. SSTR5-AS1 was distributed in cytoplasm, and it regulated its subunit integrin beta 6 (ITGB6) via eukaryotic translation initiation factor 4A3 (EIF4A3). SSTR5-AS1 shRNA inactivated ITGB6 and JAK1/STAT3 signaling. SSTR5-AS1 silencing attenuated the malignant behavior of ESCA cells through the ITGB6-mediated JAK1/STAT3 axis.Conclusion: SSTR5-AS1 promotes tumorigenesis of ESCA by interacting with EIF4A3 to regulate ITGB6/JAK1/STAT3 axis, which serves a basis for discovering strategies against ESCA.
Collapse
Affiliation(s)
- Zhaohui Tang
- Department of Oncology, The Central Hospital of Yongzhou, Hunan Province, Yongzhou, 425000, China
| | - Yongjun Jiang
- Department of Oncology, The Central Hospital of Yongzhou, Hunan Province, Yongzhou, 425000, China
| | - Yuyu Zong
- Department of Oncology, The Central Hospital of Yongzhou, Hunan Province, Yongzhou, 425000, China
| | - Sijuan Ding
- Department of Oncology, The Central Hospital of Yongzhou, Hunan Province, Yongzhou, 425000, China
| | - Chen Wu
- Department of Oncology, The Central Hospital of Yongzhou, Hunan Province, Yongzhou, 425000, China
| | - Zhangwen Tang
- Department of Oncology, The Central Hospital of Yongzhou, Hunan Province, Yongzhou, 425000, China
| | - Lin Liao
- Department of Oncology, The Central Hospital of Yongzhou, Hunan Province, Yongzhou, 425000, China
| | - Shaohui Jiang
- Department of Oncology, The Central Hospital of Yongzhou, Hunan Province, Yongzhou, 425000, China
| | - Ruoting Tang
- Department of Oncology, The Central Hospital of Yongzhou, Hunan Province, Yongzhou, 425000, China
| | - Fang Li
- Department of Oncology, The Central Hospital of Yongzhou, Hunan Province, Yongzhou, 425000, China
| | - Pengfei Luo
- Department of Oncology, The Central Hospital of Yongzhou, Hunan Province, Yongzhou, 425000, China
| |
Collapse
|
|
3
|
Han B, Ma Y, Yang P, Zhao F, Zhu H, Li S, Yu R, Bao S. Novel histone acetylation-related lncRNA signature for predicting prognosis and tumor microenvironment in esophageal carcinoma. Aging (Albany NY) 2024; 16:5163-5183. [PMID: 38478744 PMCID: PMC11006502 DOI: 10.18632/aging.205636] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2023] [Accepted: 01/02/2024] [Indexed: 04/06/2024]
Abstract
Histone acetylation is one of the most common epigenetic modifications and plays a crucial role in tumorigenesis. However, the prognostic significance of histone acetylation-related lncRNAs (HARlncRNAs) in esophageal carcinoma (ESCA) is not well understood. A total of 653 differentially expressed lncRNAs (DElncRNAs) were identified between 162 ESCA tissues and 11 normal tissues in the TCGA database, and 7 of them were correlated with acetylation regulators. We employed univariate Cox regression analysis, combining it with clinical prognosis information, to select 3 prognostic-related HARlncRNAs for further analysis. Subsequently, we used LASSO regression analysis to construct a risk signature for ESCA and identified C21orf62-AS1 and SSTR5.AS1 as potential biomarkers for the prognosis of ESCA patients. Based on the risk score calculated using the risk signature, we categorized patients into high- and low-risk groups. We identified the risk score as an independent risk factor and validated it in the training, test, and GSE53624 datasets. Additionally, patients categorized by their risk scores exhibited distinct immune statuses, tumor mutation burdens, responses to immunotherapy, and drug sensitivities.
Collapse
Affiliation(s)
- Batter Han
- Department of Thoracic Surgery, Peking University Cancer Hospital Inner Mongolia Hospital, Hohhot 010010, China
| | - Ying Ma
- Department of Thoracic Surgery, Mongolia Medical University Affiliated Hospital, Hohhot 010050, China
| | - Pengjie Yang
- Department of Thoracic Surgery, Peking University Cancer Hospital Inner Mongolia Hospital, Hohhot 010010, China
| | - Fangchao Zhao
- Department of Thoracic Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China
| | - Haiyong Zhu
- Department of Thoracic Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China
| | - Shujun Li
- Department of Thoracic Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China
| | - Rong Yu
- Department of Thoracic Surgery, Peking University Cancer Hospital Inner Mongolia Hospital, Hohhot 010010, China
| | - Subudao Bao
- Mongolian Medicine College, Inner Mongolia Medical University, Hohhot 010110, China
| |
Collapse
|
|
4
|
Wang Y, Yang W, Wang Q, Zhou Y. Mechanisms of esophageal cancer metastasis and treatment progress. Front Immunol 2023; 14:1206504. [PMID: 37359527 PMCID: PMC10285156 DOI: 10.3389/fimmu.2023.1206504] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2023] [Accepted: 05/22/2023] [Indexed: 06/28/2023] Open
Abstract
Esophageal cancer is a prevalent tumor of the digestive tract worldwide. The detection rate of early-stage esophageal cancer is very low, and most patients are diagnosed with metastasis. Metastasis of esophageal cancer mainly includes direct diffusion metastasis, hematogenous metastasis, and lymphatic metastasis. This article reviews the metabolic process of esophageal cancer metastasis and the mechanisms by which M2 macrophages, CAF, regulatory T cells, and their released cytokines, including chemokines, interleukins, and growth factors, form an immune barrier to the anti-tumor immune response mediated by CD8+ T cells, impeding their ability to kill tumor cells during tumor immune escape. The effect of Ferroptosis on the metastasis of esophageal cancer is briefly mentioned. Moreover, the paper also summarizes common drugs and research directions in chemotherapy, immunotherapy, and targeted therapy for advanced metastatic esophageal cancer. This review aims to serve as a foundation for further investigations into the mechanism and management of esophageal cancer metastasis.
Collapse
Affiliation(s)
- Yusheng Wang
- Department of Thoracic Surgery, The First People’s Hospital of Changzhou, Changzhou, Jiangsu, China
| | - Wei Yang
- Department of Gastroenterology, Kunshan Hospital of Traditional Chinese Medicine, Kunshan, Jiangsu, China
| | - Qianyun Wang
- Department of Gastroenterology, Kunshan Hospital of Traditional Chinese Medicine, Kunshan, Jiangsu, China
| | - Yong Zhou
- Department of Gastroenterology, Kunshan Hospital of Traditional Chinese Medicine, Kunshan, Jiangsu, China
| |
Collapse
|